The information on this website is intended for healthcare
professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain
information that is not applicable in your country, thus you may find
information concerning study drugs or therapeutic uses that have not
been approved by drug regulatory agencies. This website is not
intended to promote in any way, any use, either approved, or
unapproved, of a Novo Nordisk product or of any other product or serve
as basis for any treatment decision or action. Please always refer to
Summary of Product Characteristics (product label) as approved by
regulatory authorities in your country or contact Novo Nordisk for
Furthermore, the site is not intended to replace the advice of a
healthcare professional and should not be construed as providing
advice or making a recommendation. Only a physician can determine
whether a specific product is correct for a particular patient. Novo
Nordisk accepts no liability for the accuracy, completeness or use of
this information, and disclaims any liability to update the
information contained on this site.
By accessing this website you accept this legal notice and expressly
confirm your status as a healthcare professional.
ADA 2021 June 25 - 29
Semaglutide 2.4 Mg Improves Health-Related Quality Of Life In Adults With Overweight/Obesity And Type 2 Diabetes In The STEP 2 Trial
Domenica M Rubino1; Louise Faerch2; Henrik Hjorth Meincke2; Robert F Kushner3; Sue D Pedersen4; Donna H Ryan5; Sean Wharton6; Niels Zeuthen2; Ronette L Kolotkin7;
1 Washington Center for Weight Management, Arlington, VA, USA; 2 Novo Nordisk A/S, Soborg, Denmark; 3 Division of Endocrinology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 4 C-ENDO Diabetes & Endocrinology Clinic Calgary, Calgary, AB, Canada; 5 Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA; 6 York and McMaster University and Wharton Weight Management Clinic, Toronto, ON, Canada; 7 Quality of Life Consulting, Durham, NC, USA; Duke Family Medicine and Community Health, Duke University School of Medicine, Durham, NC, USA; Faculty of Health and Social Sciences, Western Norway University of Applied Sciences, Forde, Norway; Centre of Health Research, Forde Hospital Trust, Forde, Norway; Morbid Obesity Centre, Vestfold Hospital Trust, Tonsberg, Norway.;